Table 4 Indicators of the hospital use of antimicrobial agents based on consumption and expenditure in the pre-intervention and intervention periods.
AUD, mean/trimester (SD) | Preinterventiona | Interventionb | p-value |
|---|---|---|---|
Overall consumption of antimicrobials | 907.1 | 693.8 | 0.012 |
Overall consumption of antibacterial agents | 874.6 | 672.5 | 0.012 |
Overall consumption of systemic antifungal agents | 32.5 | 21.3 | 0.069 |
Consumption of carbapenems | 73.3 | 34.9 | 0.012 |
Consumption of fluoroquinolones | 181.9 | 95.8 | 0.012 |
Consumption of macrolides | 31.1 | 35.9 | 0.401 |
Consumption of metronidazole | 32.1 | 19.6 | 0.069 |
Consumption of phosphomycin | 1.9 | 5.4 | 0.012 |
Sequential therapy | 0.4 | 0.5 | 0.484 |
Anti-MSSA agents/anti-MRSA agents ratio | 1.3 | 1.8 | 0.025 |
Amoxicillin/amoxicillin-clavulanic acid ratio | 0.1 | 0.1 | 0.779 |
Amoxicillin-clavulanic acid/piperacillin-tazobactam ratio | 4.6 | 3.7 | 0.093 |
Macrolides/fluoroquinolones ratio | 0.2 | 0.5 | 0.025 |
Direct acquisition cost (€), mean/trimester (IQR) | 77044.5 | 56425.3 | 0.012 |
